S
052020
vs
K
KOSPI 200
Over the past 12 months, STCube Inc has underperformed KOSPI 200, delivering a return of +7% compared to KOSPI 200's +150% growth.
Stocks Performance
052020 vs KOSPI 200
Performance Gap
052020 vs KOSPI 200
Performance By Year
052020 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
STCube Inc
Glance View
STCube Inc. is a South Korean biotechnology company focused on antibody-based cancer treatments. It works on discovering and developing therapeutic antibodies, then testing them through preclinical and clinical development. The company’s core job is to turn early-stage science into drug candidates that could become medicines for cancer patients. STCube does not sell a large portfolio of finished drugs like a mature pharmaceutical company. It makes money mainly through research and development work, licensing deals, and collaboration agreements with other drug makers and research partners. Its customers are mostly pharmaceutical partners, hospitals, research groups, and eventually patients only if its drug candidates are approved and commercialized. What makes STCube’s business model different is that it sits early in the drug value chain. It is paid for generating promising antibody programs and related technology, not for mass-manufacturing medicines. That means its value depends on the strength of its science, the quality of its pipeline, and its ability to partner with larger companies that can help fund late-stage development and commercialization.
